FDCDDQ
OTLK icon

Federation des caisses Desjardins du Quebec’s Outlook Therapeutics OTLK Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40 Sell
25
-1,287
-98% -$798 ﹤0.01% 2981
2026
Q1 		$262 Hold
1,312
– – ﹤0.01% 2860
2025
Q4 		$2.07K Hold
1,312
– – ﹤0.01% 2593
2025
Q3 		$1.36K Hold
1,312
– – ﹤0.01% 2638
2025
Q2 		$2.1K Hold
1,312
– – ﹤0.01% 2402
2025
Q1 		$1.6K Buy
+1,312
New +$2.3K ﹤0.01% 2364

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Federation des caisses Desjardins du Quebec's OTLK Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec reduced its Outlook Therapeutics (OTLK) stake by 98% in Q2 2026, selling an estimated $798 and leaving 25 shares worth $40. The position accounts for ﹤0.01% of the portfolio, ranked #2981.

Federation des caisses Desjardins du Quebec first reported a position in OTLK in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.1K in Q2 2025. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Federation des caisses Desjardins du Quebec held 25 shares of Outlook Therapeutics worth $40 as of Q2 2026.
  • Federation des caisses Desjardins du Quebec sold 1,287 Outlook Therapeutics shares in Q2 2026, an estimated $798.
  • Outlook Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2981 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Outlook Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Federation des caisses Desjardins du Quebec's Outlook Therapeutics position peaked at $2.1K in Q2 2025.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.